These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 26828141)
1. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Etchebehere EC; Araujo JC; Milton DR; Erwin WD; Wendt RE; Swanston NM; Fox P; Macapinlac HA; Rohren EM Clin Nucl Med; 2016 Apr; 41(4):268-73. PubMed ID: 26828141 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307 [TBL] [Abstract][Full Text] [Related]
3. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640 [TBL] [Abstract][Full Text] [Related]
4. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112 [TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
6. Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients. Fiz F; Sahbai S; Campi C; Weissinger M; Dittmann H; Marini C; Piana M; Sambuceti G; la Fougère C Biomed Res Int; 2017; 2017():3905216. PubMed ID: 29435457 [TBL] [Abstract][Full Text] [Related]
15. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635 [TBL] [Abstract][Full Text] [Related]
16. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma. Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. Ahmadzadehfar H; Schlenkhoff CD; Rogenhofer S; Yordanova A; Essler M Clin Nucl Med; 2016 Sep; 41(9):695-6. PubMed ID: 27405025 [TBL] [Abstract][Full Text] [Related]
18. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study. Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867 [TBL] [Abstract][Full Text] [Related]
20. Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity. Dadhania S; Alonzi R; Douglas S; Gogbashian A; Hughes R; Dalili D; Vasdev N; Adshead J; Lane T; Westbury C; Anyamene N; Ostler P; Hoskin P; Sharma A Anticancer Res; 2018 Sep; 38(9):5423-5427. PubMed ID: 30194198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]